Forte Biosciences, Inc. (NASDAQ:FBRX) CFO Purchases $124,952.70 in Stock

Forte Biosciences, Inc. (NASDAQ:FBRX) CFO Antony A. Riley acquired 22,514 shares of the stock in a transaction dated Thursday, November 21st. The stock was bought at an average cost of $5.55 per share, with a total value of $124,952.70. Following the completion of the purchase, the chief financial officer now directly owns 30,776 shares in the company, valued at approximately $170,806.80. The trade was a 272.50 % increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link.

Forte Biosciences Stock Performance

Shares of NASDAQ FBRX opened at $16.00 on Friday. The business’s 50 day moving average price is $5.91 and its 200-day moving average price is $2.71. Forte Biosciences, Inc. has a fifty-two week low of $4.11 and a fifty-two week high of $21.25. The company has a market cap of $23.39 million, a price-to-earnings ratio of -0.98 and a beta of 0.04.

Wall Street Analyst Weigh In

Separately, Chardan Capital raised their price objective on Forte Biosciences from $3.00 to $64.00 and gave the company a “buy” rating in a research note on Friday, November 15th.

Forte Biosciences Company Profile

Forte Biosciences, Inc operates as a biopharmaceutical company in the United States. The company is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. Forte Biosciences, Inc is headquartered in Dallas, Texas.